NCT04420975 - Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions

LeiomyosarcomaMalignant Peripheral Nerve Sheath TumorMyxofibrosarcomaPleomorphic RhabdomyosarcomaResectable Dedifferentiated LiposarcomaResectable Soft Tissue SarcomaResectable Undifferentiated Pleomorphic SarcomaSoft Tissue FibrosarcomaSpindle Cell SarcomaStage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IA Retroperitoneal Sarcoma AJCC v8Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IB Retroperitoneal Sarcoma AJCC v8Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage II Retroperitoneal Sarcoma AJCC v8Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage III Retroperitoneal Sarcoma AJCC v8Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IIIA Retroperitoneal Sarcoma AJCC v8Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IIIB Retroperitoneal Sarcoma AJCC v8Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Storiform-Pleomorphic Malignant Fibrous HistiocytomaSynovial SarcomaUndifferentiated High Grade Pleomorphic Sarcoma of BoneUndifferentiated Pleomorphic SarcomaUndifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant CellsUndifferentiated Pleomorphic Sarcoma, Inflammatory VariantUndifferentiated Spindle Cell Sarcoma

Interventions

PROCEDURE

Definitive Surgical Resection

Undergo definitive surgical resection

BIOLOGICAL

Nanoplexed Poly I:C BO-112

Given intratumorally

BIOLOGICAL

Nivolumab

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles